

**MORRIS, MANNING & MARTIN, LLP**  
ATTORNEYS AT LAW**FACSIMILE  
TRANSMISSION  
FORM**1600 Atlanta Financial Center  
3343 Peachtree Road, N.E.  
Atlanta, Georgia 30326**RECEIVED  
CENTRAL FAX CENTER**

SEP 06 2006

Facsimile Number: 404-365-9532

*This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via U.S. Postal Service. Thank you.*

TO:	United States Patent & Trademark Office
DATE & TIME:	September 6, 2006
TOTAL PAGES:	Five (5)
FAX NUMBER:	571-273-8300

FROM:	Morris, Manning & Martin, LLP	CHARGE TO:	14836-46758
NAME:	Tim Tingkang Xia, Esq.	CLIENT/MATTER:	
PHONE:	(404) 233-7000	CONFIRMATION TIME:	
		HR	MIN SEC

**COMMENTS:**

Re: Serial No. 10/507,046

Filing Date: March 7, 2003

Attachments: **Transmittal  
Response to Restriction Requirement****IF YOU HAVE ANY DIFFICULTY WITH THIS TRANSMISSION, PLEASE CALL (404) 233-7000**

**RECEIVED**  
CENTRAL FAX CENTER

S/N: 10/507,046

SEP 06 2006

PATENT  
Confirmation No. 8798

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	SCHLEBUSCH, et al.	Examiner:	Unassigned
Serial No.:	10/507,046	Group Art Unit:	1641
Filing Date	September 9, 2005	Docket:	14836-46758
Title:	SPECIFIC AB1'-ANTIBODIES AGAINST TUMOUR ASSOCIATED ANTIGEN CA 125		

**CERTIFICATE UNDER 37 CFR 1.8(a):**

I hereby certify that this correspondence is being transmitted by facsimile to number 571-273-8300 addressed to Mail Stop: Non-Fee Amendment, Commissioner for Patents, United States Patent and Trademark Office on September 6, 2006.

By:   
Name: Tim Tingkang Xia

**TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


**CUSTOMER NO. 24728**

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet containing Certificate of Facsimile (1 page)
- ☒ Response to Restriction Requirement (3 pages)

MORRIS, MANNING & MARTIN, LLP  
1600 Atlanta Financial Center  
3343 Peachtree Road NE  
Atlanta, Georgia 30326  
404.495.3678  
Customer No. 24728

By:   
Name: Tim Tingkang Xia  
Reg. No.: 45,242  
TX

**RECEIVED**  
CENTRAL FAX CENTER

4043644578

T-999 P.003/005 F-477

S/N 10/507,046

SEP 06 2006

**PATENT**  
Conformation No. 8798

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Schlebusch, et al.	Examiner:	Sean E. Aeder, Ph.D.
Serial No.:	10/507,046	Group Art Unit:	1642
Filed:	September 9, 2005	Docket No.:	14836-46758
Title:	Specific AB1' Antibodies Against Tumor-Associated Antigen CA 125.		

**CERTIFICATE UNDER 37 CFR 1.8(a):**

I hereby certify that this correspondence is being transmitted by facsimile to number 571-273-8300 addressed to Mail Stop: Non-Fee Amendment, Commissioner for Patents, United States Patent and Trademark Office on September 6, 2006.

By:   
Name: Tim Tingkang Xia

**RESPONSE TO RESTRICTION REQUIREMENT**

Mail Stop: Non-Fee Amendment  
Commissioner of Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

September 6, 2006

**CUSTOMER NO. 24728**

Dear Sir:

This paper is being submitted in response to the Restriction Requirement contained in the Office Communication mailed August 7, 2006. Applicants hereby elect **without traverse** the claims of Group I, claims 1-11 for prosecution.

**Remarks begin on page 2 of this Amendment.**